A panel of medical experts break down the pathophysiology and current treatment landscape surrounding Ph+ ALL.
The following is a video synopsis/summary of a Peer Exchange involving Ryan Haumschild, PharmD, MS, MBA, CPEL; Jonathon Abbas, MD; Vivian Tambe Tar, PharmD, MBA; Elias Jabbour, MD; and James McCloskey, MD.
This Peer Exchange brings together experts in the field to discuss the clinical intricacies of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The discussion centers on the disease's rarity, affecting only a fraction of acute leukemia cases, with an emphasis on the need for personalized treatment approaches due to the diverse age range of patients.
Dr. Abbas delves into the clinical characteristics that define Ph+ ALL, highlighting its scarcity and the challenges it poses to healthcare providers. Dr. Jabbour expands on the age-related incidence of the disease, discussing peaks in pediatric and older populations. The conversation underscores the evolving landscape, with improved therapies, such as tyrosine kinase inhibitors, offering hope for better outcomes. The panel concludes by addressing gender and race neutrality while emphasizing the significance of considering comorbidities in older patients. The program anticipates a shift in treatment paradigms with targeted therapies, marking a positive trajectory in managing Ph+ ALL and enhancing patient outcomes.
Video synopsis is AI-generated and reviewed by AJMC editorial staff.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More